This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This FANCL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 274-302 amino acids from the C-terminal region of human FANCL.
FANCL
Reaktivität: Human
Wirt: Kaninchen
Polyclonal
FITC
Applikationshinweise
For WB starting dilution is: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
FANCL
(Fanconi Anemia, Complementation Group L (FANCL))
FAAP43 antikoerper, PHF9 antikoerper, POG antikoerper, 2010322C19Rik antikoerper, AW554273 antikoerper, B230118H11Rik antikoerper, Phf9 antikoerper, Pog antikoerper, gcd antikoerper, Fanconi anemia complementation group L antikoerper, Fanconi anemia, complementation group L antikoerper, FANCL antikoerper, Fancl antikoerper
Hintergrund
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity, they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms.